Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | WDR5 | P61964 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 2/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 2/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | EDNRB | P24530 | 2/20 | 0.41 |
| ▸ | EDNRA | P25101 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21384877 | 0.92 | ALDH1A1 (0.50) | ALDH1A1HSD17B10TDP1WDR5ATM | |
| 1,4-Dimethoxybenzene SCHEMBL27865602 | 0.84 | PGR (0.44) | ALDH1A1HSD17B10TDP1PGR | |
| SCHEMBL56599 | 0.83 | ALDH1A1 (0.65) | ALDH1A1HSD17B10TDP1PGRCA1 | |
| SCHEMBL31391247 | 0.81 | LMNA (0.54) | ALDH1A1WDR5ATMMMP2PGR | |
| SCHEMBL3679487 | 0.81 | LMNA (0.54) | ALDH1A1WDR5ATMMMP2PGR | |
| SCHEMBL31668877 | 0.81 | LMNA (0.54) | ALDH1A1WDR5ATMMMP2PGR | |
| SCHEMBL27365264 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TDP1WDR5ATMMMP2 | |
| SCHEMBL3035464 | 0.79 | ATM (0.46) | ALDH1A1WDR5ATMMMP2FLT1 | |
| Methane SCHEMBL28512984 | 0.78 | ALDH1A1 (0.44) | ALDH1A1TDP1WDR5ATMMMP2 | |
| SCHEMBL10633314 | 0.78 | ALDH1A1 (0.51) | ALDH1A1HSD17B10TDP1PGRCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1605 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036597-A | Compound, preparation method thereof, electrolyte and lithium ion battery | 蓝固(淄博)新能源科技有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-119425423-A | Positively charged composite membrane and preparation method and application thereof | 中国石油化工股份有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119390741-A | Morroniside derivative with antioxidant activity and synthesis method thereof | 黑龙江中医药大学 | 2025-02-07 | — | — | CN | claimed |
| CN-111472019-A | Synthesis method of N-sulfonyl azole compound | 安阳师范学院 | 2020-07-31 | — | — | CN | claimed |
| CN-106674200-A | Compound containing L-prolinamide fragment, and preparation method and application thereof | 西安交通大学 | 2017-05-17 | — | — | CN | claimed |
| CN-104678028-A | Pretreatment and detection method for biogen amine neurotransmitter and detection kit | INST PHARM & TOXICOLOGY AMMS | 2015-06-03 | — | — | CN | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| CN-119320374-B | Method for synthesizing 3-sulfonyl substituted chromone derivative by photocatalysis | JIANG University OF TECHNOLOGY (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-12630548-B2 | Azetidine derivatives for the treatment of integrin associated diseases | THE UNIVERSITY OF NOTTINGHAM (GB) | 2026-05-19 | — | — | US | disclosed |
| CN-122036597-A | Compound, preparation method thereof, electrolyte and lithium ion battery | 蓝固(淄博)新能源科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026087635-A1 | DIHYDRO BENZOXAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4713096-A1 | CDK INHIBITOR COMPOUNDS | Aleksia Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-4507315-A | Hypoglycaemic and hypolipidaemic benzamide substituted (1H-) imidazole derivatives and compositions | MAY & BAKER LIMITED (GB) | 1985-03-26 | — | — | US | disclosed |
| US-4167567-A | Antihypertensive 4-aminoquinolines | THE UPJOHN COMPANY (US) | 1979-09-11 | — | — | US | disclosed |
| US-4065618-A | Process for 3-H-3-cephem esters | ELI LILLY AND COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-4065621-A | Process for 3-alkyl and 3-phenyl cephalosporins | ELI LILLY AND COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-4013651-A | 3-SUBSTITUTED AMINO-CEPHALOSPORINS | ELI LILLY AND COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
| US-3992377-A | 3-Thio-substituted cephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1976-11-16 | — | — | US | disclosed |
| US-3985737-A | ANTIBACTERIAL AGENTS | ELI LILLY AND COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | ALDH1A1 700/4885HSD17B10 677/4885TDP1 3648/4885 |
| US-12630548-B2 | Azetidine derivatives for the treatment of integrin associated diseases | ITGA2, ITGB2, ITGB1 | ALDH1A1 814/4885HSD17B10 3114/4885TDP1 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.